DexCom

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. 

CEO
Jacob S. Leach
CEOJacob S. Leach
Employees
11,100
Employees11,100
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1999
Founded1999
Employees
11,100
Employees11,100

DXCM Key Statistics

Market cap
33.88B
Market cap33.88B
Price-Earnings ratio
35.84
Price-Earnings ratio35.84
Dividend yield
Dividend yield
Average volume
5.76M
Average volume5.76M
High today
$91.99
High today$91.99
Low today
$89.42
Low today$89.42
Open price
$91.99
Open price$91.99
Volume
3.85M
Volume3.85M
52 Week high
$91.99
52 Week high$91.99
52 Week low
$54.11
52 Week low$54.11

Stock Snapshot

DexCom(DXCM) stock is priced at $89.80, giving the company a market capitalization of 33.88B. It carries a P/E multiple of 35.84.

During the trading session on 2026-08-15, DexCom(DXCM) shares reached a daily high of $91.99 and a low of $89.42. At a current price of $89.80, the stock is +0.4% higher than the low and still -2.4% under the high.

Trading volume for DexCom(DXCM) stock has reached 3.85M, versus its average volume of 5.76M.

The stock's 52-week range extends from a low of $54.11 to a high of $91.99.

The stock's 52-week range extends from a low of $54.11 to a high of $91.99.

DXCM News

MarketWatch 19h
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch

...

DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Simply Wall St 3d
Is DexCom Fully Valued Following Strong Earnings And Higher Revenue Guidance?

DexCom (DXCM) is back in focus after its latest quarterly update, which combined higher second quarter revenue and net income with a raised full year sales outl...

Is DexCom Fully Valued Following Strong Earnings And Higher Revenue Guidance?
Nasdaq 3d
DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?

DexCom DXCM stock has rebounded sharply in 2026, gaining 34.8% after falling 14.7% in 2025, as investors increasingly recognize the company’s improving growth p...

DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
19.4%
Sell
0%

More DXCM News

Simply Wall St 5d
Stronger Q2 Results and Higher 2026 Outlook Might Change The Case For Investing In DexCom

In July 2026, DexCom, Inc. reported second-quarter results showing higher sales of US$1,308.4 million and increased net income of US$249.1 million compared with...

Stronger Q2 Results and Higher 2026 Outlook Might Change The Case For Investing In DexCom

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.